Full Press Release Details
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately.
“I am thrilled to welcome Laura to the Aligos team,” said Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos. “Laura brings with her a wealth of experience in all legal aspects from both biotech companies as well as large pharmaceutical firms. Her extensive knowledge and broad expertise will undoubtedly provide invaluable leadership and oversight on all legal matters.”
“I am honored to join the dynamic team at Aligos,” stated Laura Kavanaugh, Vice President, Head of Legal at Aligos. “I look forward to working with my new colleagues to navigate the complex legal landscape to drive forward our mission of improving patient outcomes.”
Ms. Kavanaugh joins Aligos with more than 25 years of experience as an attorney and leader in the biotechnology and pharmaceutical industries. Most recently, she served as Vice President, Corporate Law & Privacy Officer at Codexis. Previously, Ms. Kavanaugh was an independent legal consultant for clients including Genentech, Elan Pharmaceuticals, Allakos, ZS Pharma, and Principia. She also held roles of increasing responsibility at Elan Pharmaceuticals and at Genentech, where she ultimately served as Practice Group Leader, BioOncology Development Law. Her career began as an associate at a prominent Silicon Valley law firm. Ms. Kavanaugh earned a BA from the University of California, Berkley and a JD from Santa Clara University Law School.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Vice President, Investor Relations & Corporate Communications